Krishnansu Tewari, MD

Articles

The Future of Clinical Care for Patients With Advanced Endometrial Cancer

October 6th 2023

Closing their conversation, Ramez Eskander, MD, and Krishnansu Tewari, MD, share how they envision the future treatment landscape for patients with advanced endometrial cancer.

Emerging Targeted Treatment Options for Patients With Advanced Endometrial Cancer

October 6th 2023

Key opinion leaders discuss targeted treatment regimens for advanced or recurrent endometrial cancer that are currently under development.

Patient Profile Presentation: A 68-Year-Old Woman With Recurrent Endometrial Cancer

September 29th 2023

Krishnansu Tewari, MD, presents the profile of a 68-year-old postmenopausal woman with recurrent endometrial cancer for discussion.

Approaches to Treatment Sequencing for Patients With Advanced Endometrial Cancer

September 29th 2023

Experts explain how they change their treatment strategies if a patient with advanced endometrial cancer does not respond to treatment or experiences disease progression.

Recent Data on IO-Based Combination Regimens for First-line Treatment of Advanced Endometrial Carcinoma

September 22nd 2023

Krishnansu Tewari, MD, reviews emerging data from two studies investigating immunotherapy-based combination regimens for the first-line treatment of advanced endometrial cancer.

Available Frontline Treatment Options for Patients With Advanced or Recurrent Endometrial Cancer

September 22nd 2023

Krishnansu Tewari, MD, details the first-line treatment options for patients with recurrent endometrial cancer.

Patient Profile Presentation: A 64-Year-Old Woman With Recurrent Endometrial Cancer

September 15th 2023

Ramez Eskander, MD, presents the profile of a 64-year-old postmenopausal woman diagnosed with recurrent endometrial carcinoma for discussion.

Overview of Endometrial Carcinoma

September 15th 2023

Ramez Eskander, MD, and Krishnansu Tewari, MD, provide an overview of endometrial cancer, including prevalence, staging criteria, and molecular profiling.

Sequencing Therapy for MSI-High and MMR-Proficient Endometrial Carcinomas

April 4th 2022

A discussion on the best way to sequence therapies for patients with MSI-high and MMR-proficient endometrial carcinoma.

Endometrial Carcinoma: Clinical Case Scenario 3

March 24th 2022

Oncologists debate the proper treatment of a patient with a grade 2 endometrial carcinoma tumor.

Trastuzumab in Endometrial Carcinoma Therapy

March 24th 2022

Dr David O’Malley explains when to add and remove trastuzumab during endometrial carcinoma therapy.

I/O + Chemotherapy Treatments for Endometrial Carcinoma

March 18th 2022

A review of data from several clinical trials on the use of I/O + chemotherapy as treatment for endometrial carcinoma.

Endometrial Carcinoma: Clinical Case Scenario 2

March 18th 2022

Experts explain the need for germline testing and genetic counseling for patients with endometrial carcinoma as demonstrated by a patient case.

Dose Reduction in Endometrial Carcinoma Treatment

March 10th 2022

Drs Bradley Monk and David O’Malley explain dose reduction in endometrial carcinoma treatment based on clinical trial data.

Treatment Options for Advanced Stage Relapsed Endometrial Carcinoma

March 10th 2022

Physician-researchers discuss the risk of recurrence in endometrial carcinoma and the available treatment options after relapse.

Biomarker Testing in Endometrial Carcinoma

March 4th 2022

An overview of biomarker testing in endometrial carcinoma.

Endometrial Carcinoma: Clinical Scenario 1

March 4th 2022

Oncologists describe a typical presentation of endometrial carcinoma and debate the implications of radiation treatment.

Metastatic Cervical Cancer: Interpreting Data From KEYNOTE-826

November 18th 2021

Experts take a closer look at the data points from KEYNOTE-826 to consider pembrolizumab’s potential role in metastatic cervical cancer management.

Dr. Tewari on the Trial Design With Cemiplimab in Cervical Cancer

October 4th 2018

Krishnansu Tewari, MD, associate professor, Division of Gynecologic Oncology, University of California, Irvine, discusses the trial design with cemiplimab (Libtayo) in recurrent or metastatic cervical cancer.

Dr. Tewari on Immunotherapeutic Strategies in Cervical Cancer

August 3rd 2018

Krishnansu Tewari, MD, associate professor, Division of Gynecologic Oncology, University of California, Irvine, discusses immunotherapeutic strategies in cervical cancer.